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Abstract 
Background: Introduction of nitisinone and newborn screening (NBS) have transformed the treatment of type 1 
tyrosinemia, but the effects of these changes on the long-term outcomes remain obscure. Also, the predictors for 
later complications, the significance of drug levels and the normalization of laboratory and imaging findings are 
poorly known. We investigated these issues in a nationwide study.
Results: Type 1 tyrosinemia was diagnosed in 22 children in 1978–2019 in Finland. Incidence was 1/90,102, with a 
significant enrichment in South Ostrobothnia (1/9990). Median age at diagnosis was 5 (range 0.5–36) months, 55% 
were girls and 13 had homozygotic Trp262X mutation. Four patients were detected through screening and 18 clini-
cally, their main findings being liver failure (50% vs. 100%, respectively, p = 0.026), ascites (0% vs. 53%, p = 0.104), renal 
tubulopathy (0% vs. 65%, p = 0.035), rickets (25% vs. 65%, p = 0.272), growth failure (0% vs. 66%, p = 0.029), throm-
bocytopenia (25% vs. 88%, p = 0.028) and anaemia (0% vs. 47%, p = 0.131). One patient was treated with diet, seven 
with transplantation and 14 with nitisinone. Three late-diagnosed (6–33 months) nitisinone treated patients needed 
transplantation later. Kidney dysfunction (86% vs. 7%, p = 0.001), hypertension (57% vs. 7%, p = 0.025) and osteope-
nia/osteoporosis (71% vs. 14%, p = 0.017) were more frequent in transplanted than nitisinone-treated patients. Blood/
serum alpha-fetoprotein decreased rapidly on nitisinone in all but one patient, who later developed intrahepatic 
hepatocellular carcinoma. Liver values normalized in 31 months and other laboratory values except thrombocyto-
penia within 18 months. Imaging findings normalized in 3–56 months excluding five patients with liver or splenic 
abnormalities. Low mean nitisinone concentration was associated with higher risk of severe complications (r = 0.758, 
p = 0.003) despite undetectable urine succinylacetone.
Conclusions: Prognosis of type 1 tyrosinemia has improved in the era of nitisinone, and NBS seems to provide fur-
ther benefits. Nevertheless, the long-term risk for complications remains, particularly in the case of late diagnosis and/
or insufficient nitisinone levels.
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Background
Tyrosinemia is an autosomal recessively inherited meta-
bolic disease presenting with three clinically distinct sub-
types. The majority of patients have type I tyrosinemia 
(TT1, OMIM 276,700), types II and III being extremely 
rare [1–3]. The global incidence is ~ 1/100,000–
1/200,000, but TT1 has enriched in certain areas, par-
ticularly in Northern Europe and Canada [4–7]. The 
disease is caused by a homozygous or compound het-
erozygous mutation in the gene on chromosome 15q25, 
leading to a lack of fumarylacetoacetate hydrolase (EC 
3.7.1.2) and an ensuing accumulation of blood tyrosine, 
succinylacetoacetate and succinylacetone (SA) [6, 8, 9]. 
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Typical presentation includes liver failure and kidney 
tubular dysfunction, other reported findings being, for 
example, growth failure, rickets and pseudo-porphyric 
crises [6, 9–12]. Untreated TT1 increases the risk for 
liver carcinoma [12, 13].
Liver transplantation was the only cure for TT1 until 
the discovery of nitisinone [14]. Although the drug is 
effective in preventing the production of toxic metabo-
lites, the accumulation of tyrosine must be prevented 
by protein restriction [11]. Furthermore, although data 
is scarce, nitisinone-treated patients may also develop 
complications [6, 15, 16], particularly in the case of 
delayed diagnosis or persistently high tyrosine levels [6]. 
However, optimal long-term concentrations of plasma 
nitisinone and tyrosine are unclear. Newborn screening 
(NBS) has improved the short-term outcomes of TT1 
patients [16, 17], but long-term results are still lacking 
[12]. Altogether, natural history studies of TT1 in the era 
of nitisinone and NBS are scant and have concentrated 
on a few geographical areas [16].
In Finland, the treatment of TT1 is centralized, with 
systematically maintained medical records and NBS 
programmes launched in 2014. This has enabled us to 
evaluate the incidence, changing features and long-term 
outcomes of TT1 in a nationwide setting.
Results
Incidence, family background and genetics
Twenty-one patients were diagnosed in the period 
1987–2018, and one in 1978. Additional search resulted 
in > 2000 metabolic/liver patients, none of whom had 
TT1. Incidence was 1/90,102 with significant enrich-
ment in South Ostrobothnia (Fig.  1a), the area from 
which most patients originated (Fig.  1b). Two patients 
were of non-Finnish origin, and one of these had con-
sanguineous parents. Three families had a history of 
TT1. Thirteen patients had a homozygous Finnish 
type c.786G > A, (p.Trp262X) mutation. Four patients 
had a compound heterozygous mutation, including 
Trp262X + c.1062 + 5G > A (p.?), Trp262X + unidentified 
other mutation, c.205del (p.Ser69fs) + c.554-1G > T (p.?) 
and c.191delA (p.Gln64fs) + c.191delA (p.Gln64fs). The 
latter two patients were originally from Kosovo and Iraq.
Pregnancy and neonatal data
No pregnancy complications were reported. Median 
births weight was 0.1 (− 1.4 to 2.2) SD, length 0.4 (range 
− 1.3 to 3.8) SD, and head circumference 0.1 (− 1.3 to 
1.8) SD. Of note, glucose value was measured in 20 out 
of the 22 newborns, and 45% of them needed intensi-
fied surveillance due to hypoglycaemia and 30% due to 
transient hypotonia. Five hypoglycaemic patients needed 
oral glucose supplementation and four intravenous 
infusion for a few days. Three of those with hypoglycae-
mia received TT1 diagnosis by NBS. Glucose value is 
measured frequently from Finnish newborns before dis-
charging them from hospital.
Characteristics at diagnosis
Twelve (55%) patients were girls and the median age was 
5 (range 0.5–36) months. Eighteen patients were found 
clinically, the main findings including acute abdomen 
(n = 8), septicaemia (n = 4), ascites (n = 3), rickets (n = 2) 
and intestinal bleeding (n = 1). Three were found by NBS 
and one by family screening. They had fewer clinical 
(Table 1), laboratory (Table 2) and imaging abnormalities 
(Table 3) and higher calcium and prothrombin time (PT) 
and lower conjugated bilirubin levels (Table 2) than those 
detected clinically. One patient had kidney dysfunction 
(increased plasma creatinine and urea, oliguria) while 11 
had tubulopathy (acidosis and abnormal urine protein 
and/or glucose and/or microglobulin). Median height 
was − 1.3 (− 1.8 to 0.1) SD in screened and − 1.7 (− 3.1 
to 0.7) SD in clinically-detected patients (p > 0.05) respec-
tively. Three clinically-detected children had bilateral and 
two unilateral inguinal hernia and two also scrotum her-
nia; they all had ascites.
Initial treatment and short‑term outcomes
One patient was treated with diet and seven with trans-
plantation. One explant contained hepatocellular carci-
noma, six cirrhosis and four cell atypia. Fourteen patients 
started nitisinone (median 1.0, range 0.9 –1.3  mg/kg/
day). Eleven of them had dietary challenges and two 
needed temporary gastrostomy. Median hospitalization 
time, including the time before and after diagnosis and 
during liver transplantation, was 150 (range 78–195) days 
for children before the nitisinone era and 17 (2–45) days 
for children on nitisinone (p < 0.001).
Long‑term outcomes
Median follow-up time of all patients was 16 (range 3–32) 
years and 12 (3–24) years on nitisinone. One patient died 
(at the age of 7  years) before the era of transplantation, 
one (29 years) with transplant due to unknown cause and 
one (15 years) later transplanted patient for intracerebral 
haemorrhage. Median age of the surviving patients was 
12 (3–24) years on nitisinone and 30 (29–32) with initial 
liver transplant.
Kidney dysfunction, hypertension and reduced 
bone mineral density were more common in trans-
planted than among nitisinone-treated patients, but 
not after adjusting for current age (Table  4). Four 
patients needed liver re-transplant(s) and one kid-
ney transplant due to severe kidney dysfunction after 
liver transplantation, and four patients had surgical 
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complications. Three late-diagnosed (6–33  months) 
patients on nitisinone also needed transplant due to 
elevation of alpha-fetoprotein (AFP) and new/persist-
ing nodules in imaging studies raising suspicion of 
intrahepatic malignancy. One of them had non-meta-
static hepatocellular carcinoma and two had cirrhosis. 
One nitisinone-treated patient had pseudo-porphy-
ric crisis while having undetectable urine SA but low 
serum nitisinone (13 µmol/l). None had eye complica-
tions. Three screen-detected patients also had subse-
quent health problems (developmental delay, learning 
difficulties, osteopenia). Median adult height was − 1.4 
(− 0.5 to − 3.9) SD in nitisinone-treated and − 1.5 (0.2 
to − 2.0) SD in transplanted patients (p = 0.639).
Predictors for long‑term complications
Males had more often ≥ 2 complications (100% vs. 
50%, p = 0.015), whereas there was no association 
between complications and age or clinical presenta-
tion at diagnosis. Those with multiple complications 
had lower median calcium (r = −0.447, p = 0.055) and 
higher creatinine (r = 0.496, p = 0.036), alkaline phos-
phatase (ALP, r = 0.483, p = 0.027) and gamma-gluta-
myl transferase (γ-GT, r = 0.547, p = 0.019) levels at 
diagnosis, and lower nitisinone levels during follow-up 
(r = −0.758, p = 0.003). Growth delay at diagnosis also 
predicted later growth disturbances (p = 0.045).
a 
South 
Ostroboth-
nia
> 1/10 000
1/10 000–50 000
< 1/100 000
no cases
b
FINLAND
SWEDEN
RUSSIA
Tampere
Oulu
Helsinki
Turku
Fig. 1 Incidence of type 1 tyrosinemia in 19 Finnish provinces (a) and the family origins of the patients (b)
Page 4 of 11Äärelä et al. Orphanet J Rare Dis          (2020) 15:281 
Normalization of the laboratory and imaging results
Serum AFP decreased steadily on nitisinone except in 
one patient with later malignancy (Fig. 2a), while tyros-
ine and nitisinone levels varied markedly (Fig.  2b, c). 
In transplanted patients, AFP persisted (Fig.  2a) and 
tyrosine was kept low until operation (Fig.  2b). Conju-
gated bilirubin normalized in 10–550  days, albumin in 
58–60 days, and haemoglobin in 3–90 days on nitisinone. 
Thrombocytopenia normalized in 3–90  days, except in 
three patients, of whom two were later transplanted. All 
three had persistent or reappearing splenomegaly. Acido-
sis and tubulopathy disappeared within three months and 
urine SA within one month. Normalization of the other 
values is presented in Figs. 3 and 4.
Liver imaging abnormalities persisted until transplan-
tation. On nitisinone, they normalized in 10/13 patients 
within 56 months; two of the three with persistent find-
ings were later transplanted. Splenomegaly normalized 
within 56  months except in two transplanted patients 
and one (diagnosed at 8  months) nitisinone-treated 
patient. It also appeared later in two transplanted 
and three nitisinone-treated (diagnosis 5–33  months) 
patients of whom four developed liver complications. 
Kidney, central nervous system (CNS) and cardiac find-
ings and rickets normalized within 56 months. However, 
5/6 transplanted and 1/6 nitisinone-treated patients with 
rickets later developed osteopenia/osteoporosis. None 
of the NBS patients had persistent laboratory or imaging 
abnormalities and thus none needed transplantation.
Long‑term nitisinone treatment, tyrosine levels 
and protein intake
The median nitisinone dose (n = 13) was 1.00 (range 
0.69–1.83) mg/kg/day and the mean serum level of 212 
measurements 56 (12–97) µmol/l. There was no corre-
lation between the levels and dosing or taking the drug 
once (n = 3) or twice a day (n = 10). Urine SA remained 
Table 1 Clinical findings at diagnosis in clinically-detected 
and screen-detected patients with type 1 tyrosinemia
a Data missing for 1 patient
b Data missing for 2 patients
Clinically‑
detected, 
n = 18
Screen‑
detected, 
n = 4
P value
n % n %
Symptoms
Fever 9 50.0 0 0 0.115
Recurrent vomiting 7 38.9 0 0 0.263
Melena/haematochezia 5 27.8 0 0 0.535
Diarrhoea 4 22.2 0 0 0.554
Clinical findings
Liver failure 18 100.0 2 50.0 0.026
Growth failure 12 66.6 0 0 0.029
Kidney tubulopathy 11a 64.7 0 0 0.035
Jaundice 1 5.6 0 0 0.999
Laboratory findings
Thrombocytopenia 15a 88.2 1 25.0 0.028
Metabolic acidosis 12b 75.0 1 25.0 0.101
Hypoglycaemia 9 50.0 2 50.0 0.999
Anaemia 8a 47.1 0 0 0.131
No symptoms or findings 0 0 1 25.0 0.182
Table 2 Laboratory findings at diagnosis in clinically-detected and screen-detected patients with type 1 tyrosinemia
AFP alpha-fetoprotein, ALT alanine aminotransferase, DBil conjugated bilirubin, γ-GT γ-glutamyl transferase, NH4+ ammonium ion, PT, prothrombin time, TBil total 
bilirubin
a Data available
Clinically‑detected, n = 18 Screen‑detected, n = 4 P value
na Median Range na Median Range
Age, months 18 6 2–36 4 1 0–31 0.098
AFP, kU/l 16 148,725 5990–420,800 4 82,868 6470–487,300 0.682
ALT, U/l 17 45 15–111 4 32 10–63 0.362
Calcium, mmol/l 15 2.15 1.26–2.70 4 2.60 2.34–2.60 0.014
Creatinine, μmol/l 14 25 12–103 4 27 24–32 0.327
DBil, μmol/l 12 17 6–38 4 5 3–11 0.013
γ-GT, U/l 14 136 43–328 4 99 91–134 0.327
NH4+ , μmol/l 15 74 36–141 4 65 38–87 0.530
Phosphate, mmol/l 16 0.86 0.22–2.64 4 1.85 0.77–2.19 0.064
PT,  % 16 11 0–37 4 35 15–68 0.029
TBil, μmol/l 17 30 16–48 4 61 14–106 0.144
Tyrosine, μmol/l 16 384 100–840 4 490 452–734 0.099
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constantly negative even with low nitisinone. Median 
protein intake during nitisinone was 2.2 (1.0–3.0) and 
2.0 (1.3–3.0) mg/kg/day before and after one year of age 
respectively, and the ratio between natural and tyrosine/
phenylalanine-free protein 0.7 (0.2–1.1) and 0.8 (0.3–2.0). 
Higher natural and modified protein ratio increased the 
likelihood of later transplantation (p = 0.007).
Low serum nitisinone was associated with later com-
plications, these being present in six patients with mean 
value ≤ 54  µmol/l and none with > 54  µmol/l (AUC 0.85 
[0.63–1.00]; p = 0.040). This was seen particularly with 
growth failure (0.93 [0.78–1.00], p = 0.028) and later 
transplantation (0.93 [0.78–1.00], p = 0.028). Also, low 
minimum nitisinone was associated with learning dif-
ficulties (0.86 [0.64−1.00], p =  0.045); three out of four 
children with minimum ≤ 24  µmol/l and 1/9 of those 
with > 24  µmol/l). Neither the type nor the number of 
complications was associated with tyrosine levels or vari-
ability of those levels.
Discussion
We found the incidence of TT1 to be 1/90,102 in Fin-
land, with a significant enrichment (1/9,990) in South 
Ostrobothnia. The latter is likely due to the homogenous 
population and overrepresentation of inherited diseases 
in this area [18]. In central Europe the corresponding fig-
ure is ~ 1/100,000–200,000 [6, 19], in Norway 1/74,800 
[7] and in Quebec (Canada) up to 1/16,000 [4], whereas 
in Japan TT1 is exceptional [1]. As a further supporting 
founder effect, most patients living in South Ostroboth-
nia had homozygotic “Finnish type” Trp262X mutation 
[5] and their ancestors also originated from there. The 
other mutations were c.1062 + 5G > , which is common in 
Quebec [16, 20], c.191delA common in Turkey [21] and 
“Mediterranean” c.554-1G > T [20]. Of note, one patient 
had a previously unreported c.205del (p.Ser69fs) muta-
tion [20].
Clinical presentations were mostly in line with earlier 
reports [6, 16, 17, 19, 22–27], the main findings includ-
ing e.g. liver failure, poor growth and rickets. Pregnan-
cies had also been uneventful [17, 23], but quite many 
had temporary hypoglycaemia or hypotonia after birth 
and five presented with inguinal/scrotum hernias, likely 
due to ascites [28]. These previously unreported findings 
should be kept in mind as possible early signs of TT1 in 
high-prevalence areas. Inexplicably, we found no cases 
with frequently described [16, 19, 22, 29] cardiomyopa-
thy and neurological crises. Of note, although according 
to laboratory parameters most of the patients had deep 
coagulopathy typical for TT1 [22, 24, 29], severe bleeding 
was rare.
The number of screen-detected patients was low, but 
their milder phenotype compared with those detected 
Table 3 Radiological findings at  diagnosis in  clinically-
detected and  screen-detected patients with  type 1 
tyrosinemia
The conducted imaging studies included wrist X-ray, abdominal, cardiac and 
cranial ultrasound and liver and brain magnetic resonance imaging or computer 
tomography. Cardiac ultrasound was available for 19 patients, Central nervous 
system (CNS) imaging was done for 16 patients and the other imaging studies 
for all 21 patients
a Two cases with resolving cerebral atrophy and one craniopharyngioma
b One mild mitral regurgitation and one atrium septum defect
Clinically‑
detected, n = 17
Screen‑detected, 
n = 4
P value
n % n %
Hepatic nodules 17 100 2 50.0 0.029
Rickets 11 64.7 1 25.0 0.272
Hepatomegaly 10 58.8 1 25.0 0.311
Renomegaly 10 58.8 1 25.0 0.311
Ascites 9 52.9 0 0 0.104
Splenomegaly 6 35.3 0 0 0.281
CNS findings 3a 21.4 0 0 0.999
Cardiac findings 2b 13.3 0 0 0.999
No findings 0 0 1 25.0 0.190
Table 4 Long-term complications in  tyrosinemia patients 
treated primarily either  with  liver transplantation 
or with nitisinone medication
a One patient needed kidney transplant
b The patient had received liver transplant before the development of kidney 
dysfunction
c All patients with hypertension had received liver transplant and two had 
secondary cardiac hypertrophy
d Two patients had seizures, one had seizure in childhood and porphyrin crises 
at the age of 13 years, and one had facial paresis
e−h P = 0.999 for each if adjusted for current age. Kidney dysfunction and 
hypertension appeared at the age of 14–25 years, osteoporosis/osteopenia and 
fractures at the age of 6–20 years, neurological symptoms/developmental delay 
at the age of 3–17 years and growth failure at the age of 1–3 years
Transplantation, 
n = 7
Nitisinone, 
n = 14
P value
n % n %
Kidney  dysfunctiona 6 85.7 1b 7.1 0.001e
Hypertensionc 4 57.1 1 7.1 0.025f
Osteopenia/osteoporosis 5 71.4 2 14.3 0.017 g
Osteoporotic fractures 2 28.6 0 0.0 0.100
Growth failure 2 28.6 3 21.4 0.999
Learning difficulties 4 57.1 4 28.6 0.346
Neurological  symptomsd 2 28.6 2 14.3 0.440
Developmental delay 1 14.3 2 14.3 0.999
Any complication 7 100 8 57.1 0.061 h
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clinically was evident. Moreover, in line with ear-
lier short-term studies [6, 13, 22, 29], early detection 
seemed to improve the prognosis; all subjects needing 
transplantation despite nitisinone had late diagnosis. 
As regards the benefits of NBS, the current evidence is 
again based mainly on short-term reports [6, 17, 29], an 
exception being a Canadian study which found none of 
the NBS patients to have significant liver problems after 
5–10  years [16]. However, like some other groups [6, 
17, 29] we observed signs of hepatic dysfunction which, 
together with the aforesaid neonatal symptoms, suggests 
disease progression already in utero [17, 30]. The fre-
quency of neonatal hypoglycaemia was also surprisingly 
high. Although this could be due in part to the sensitive 
screening performed frequently on Finnish newborns, 
it may also be TT1-related, and further studies on this 
interesting issue are needed. Risk of later health problems 
emphasizes the need for careful follow-up also for 
screen-detected patients [6].
Basic laboratory values and liver function tests nor-
malized rapidly in most cases, while this took longer 
in case of transaminases and biliary parameters. This 
is mostly in line with earlier reports [17, 19, 23, 25], 
although the follow-up time has usually been shorter. 
Transaminase levels were higher and normalized more 
slowly than described before [16, 23], but this did not 
predict later complications. Some children also presented 
with high ammonium ion (NH4 +), this being feared to 
predict early need for transplantation [11], but the val-
ues decreased promptly on nitisinone. Slow decline of 
AFP is a physiological phenomenon in infancy [30, 31], 
but our findings confirm that nondecreasing or rerising 
values predict malignancy [16, 19, 22, 32]. Of note, per-
sistent thrombocytopenia, which was associated with 
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splenomegaly and is a classical sign of a chronic liver dis-
ease, was also a strong predictor of subsequent need for 
transplantation.
The kidney, CNS, cardiac and bone imaging find-
ings normalized within a few years, but some patients 
had persistent liver abnormalities and/or splenomegaly. 
Comparable gradual improvement in renal findings has 
also been reported by a British group [25] whereas clini-
cally important data about the disappearance of the other 
findings or significance of their perseverance has been 
limited. Persistent liver abnormalities have been reported 
in 19–57% of patients, but the follow-up times have been 
shorter than in the present study [6, 16, 17, 19, 23, 29]. 
Here the nonresponsive findings and reappearance of 
splenomegaly were major warning signs for subsequent 
hepatic transplantation.
Long-term complications of TT1 were mostly analo-
gous with those reported in the literature [15–17, 19, 
25, 29, 33, 34]. Neurological problems and poor growth 
were more common here, but the follow-up times of 
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these earlier studies may have been too short to detect 
these late-appearing issues. The former have been sug-
gested to be partially attributable to the side effects of 
nitisinone [34, 35], but this is debatable [33, 36] and 
here low levels seemed more harmful. However, early 
disease onset seems to increase the risk for neurological 
complications [6], again supporting the idea of in utero 
progression of TT1. Poor growth has been sparsely 
 reported28, but the possible risk for short stature 
observed here calls for further studies. The association 
observed between low mean nitisinone and growth fail-
ure may be due to inadequate treatment and ongoing 
liver disease. Then again, these same patients needed 
liver transplant despite nitisinone use, and hence the 
role of transplantation must also be considered. There 
is also limited and inconsistent data about the preva-
lence and appropriate follow-up of bone issues in TT1 
[12, 16], but our results suggest that surveillance at 
least for cases with rickets at diagnosis is warranted. In 
contrast, as in prior short-term studies [17, 19, 23, 25, 
29], persistent renal involvement seems to be rare.
We found no significant association between long-
term complications and tyrosine levels, but low serum 
nitisinone, even with negative urine SA, was associated 
with learning difficulties, growth delay and a need for 
transplantation. The reported nitisinone target range 
has varied 20–80 µmol/l [6, 11, 37] and the dosing usu-
ally aims to achieve negative urine SA [6, 24]. Optimal 
levels remain somewhat unclear, but frequent monitor-
ing of the levels with a target of 40–60 µmol/l has been 
recommended [12]. Interestingly, recent studies have 
reported increased blood SA with nitisinone concen-
trations < 44.3  µmol/l [38] and positive urine SA with 
nitisinone < 40 µmol/l, respectively [39]. Thus, there may 
in theory have been intermittent SA secretion in our 
patients with low mean nitisinone levels even without 
detectable urine SA at follow-up visits. Urine SA var-
ies depending on urine concentration and blood meas-
urement may be more stable and replicable indicator 
of ongoing SA production [40]. Thus, the latter in com-
bination with the nitisinone level could thus be prefer-
able as a follow-up marker [38–40]. Interpretation of the 
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markedly fluctuating nitisinone values can be difficult, 
but our results underline the importance of sufficient lev-
els, which may be even higher than previously suggested. 
Of note, the increased ratio of natural to modified pro-
tein was also associated with subsequent need for liver 
transplantation in nitisinone-treated patients. This may 
be related to generally higher tyrosine levels, although 
we found no statistically significant association between 
tyrosine levels and complications.
The main strengths of the present study were the 
nationwide coverage and availability of comprehensive 
medical data. Detailed registers also provided informa-
tion on long-term outcomes and enabled us to assess risk 
factors for later complications, although weaknesses in 
the retrospective design remain. As a further limitation, 
an intensified register search was conducted in only one 
district, which in theory could have led to a few earlier 
cases being missed. Some patients may also have died 
before the transplantation era and were thus lost since 
medical records are deleted 12 years posthumously.
Conclusions
The overall prognosis of TT1 has improved in the 
nitisinone era and NBS seems to provide further benefits. 
However, clinicians should realize that a risk of complica-
tions persist even among screen-detected patients. Inten-
sified surveillance is warranted, especially in patients 
with delayed diagnosis and persistent laboratory or imag-
ing abnormalities. In addition, maintaining sufficient 
nitisinone levels is important.
Methods
Study design and patients
Treatment of metabolic disorders in Finland is central-
ized in the university hospitals of Tampere (TAYS), Hel-
sinki, Turku, Oulu and Kuopio. Patients with TT1 were 
searched from these centres by contacting the physi-
cians responsible and by applying International Classi-
fication of Diseases code E70.2. In addition, since TAYS 
was known to diagnose most of the TT1 patients due its 
location near South Ostrobothnia, an intensified search 
among children with metabolic disease or liver failure 
diagnosed since 1960 was conducted there. Some follow-
up visits took place in the central hospitals of Seinäjoki 
and Satakunta, and this data was also obtained. After 
patient identification, comprehensive medical data on 
each case was collected from birth until Sept. 2019.
Clinical characteristics and family background
The date of diagnosis was defined as the first positive 
urine SA, also in the case of NBS performed initially from 
dried blood spot. TT1 became part of the Finnish NBS 
programme in 2014 and currently 97% of newborns are 
tested. Positive blood spot screening result is confirmed 
by urinary SA measurement. If SA is negative, false 
positive NBS is confirmed by measuring plasma amino 
acids and urine organic acids [12, 41]. The collected data 
comprised a diagnostic approach (clinical suspicion vs. 
screening), demographic data, symptoms and clinical 
findings, developmental stage and growth parameters 
[42, 43] and relevant data about pregnancy and delivery. 
In addition, the origins of patients’ grandparents or the 
birthplace of the patient, presence of other TT1 cases in 
the family and possible consanguinity were documented.
Laboratory and imaging findings
The collected blood values included alanine aminotrans-
ferase (ALT), albumin, ALP, AFP, NH4+, blood count, 
calcium, γ-GT, glucose, PT and total (TBil) and conju-
gated bilirubin. The presence of liver or kidney dysfunc-
tion, kidney tubulopathy, anaemia, thrombocytopenia 
and hypoglycaemia [11, 26, 44–46] were also recorded. 
Liver dysfunction was diagnosed by the clinician based 
on the presence of characteristic findings (e.g. coagu-
lopathy, hypoglycaemia, hypoalbuminemia, low choles-
terol, increased  NH4+). Kidney tubulopathy was based 
on the presence of acidosis and abnormal urine protein 
and/or glucose and/or microglobulin. During nitisinone 
treatment, the above-mentioned laboratory values, blood 
tyrosine and nitisinone levels and urine SA were moni-
tored until current date. In transplanted patients, AFP 
and tyrosine values were monitored until transplantation.
The presence of ascites, abnormalities of liver, spleen, 
kidney, heart and CNS and the presence of rickets and 
osteopenia/osteoporosis were evaluated using X-rays, 
ultrasound, computer tomography, magnetic resonance 
and bone densitometry. Besides diagnostic imaging, at 
least annual abdominal surveillance was conducted in all 
patients. The disappearance of the abnormalities and the 
appearance of new findings were also documented.
Treatment
Possible treatment modalities included sole dietary 
restriction, liver transplantation and nitisinone. Histol-
ogy of the explants and possible transplantation com-
plications were recorded, as were the compliance to and 
dosing (mg/kg/day) of nitisinone.
Long‑term outcomes
Possible later complications were categorized to surgical 
complications, need for retransplant or transplantation 
despite nitisinone, kidney dysfunction, hypertension, 
pseudo-porphyric crises [11, 12, 47], osteopenia/osteo-
porosis, cardiac and ophthalmologic complications, 
delayed growth and neurological problems [11]. Kidney 
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dysfunction was defined as decreased glomerular filtra-
tion rate. Cause of death were also noted.
Statistical analysis
Categorical variables are reported as numbers and per-
centages, and numerical data as medians with quartiles 
or ranges. Comparisons were made with Mann–Whit-
ney test, Chi-square or Fisher’s exact test as appropri-
ate. Associations between diagnostic findings and later 
complications were analysed with Spearman’s correlation 
and binary logistic regression, which was used for age 
adjustments, and those between nitisinone and tyrosine 
levels and complications with ROC [48] and crosstabu-
lation. The possible association between low minimum 
nitisinone level (the lowest level of an individual patient 
during treatment) and later complications was also tested 
for each patient. Levels measured at the beginning of 
treatment while still adjusting the dosage were excluded. 
Similarly, the association between mean nitisinone and 
tyrosine levels (all values measured during follow-up vis-
its) and risk for later complications was assessed. Specifi-
cally, ROC curve and crosstabulation were used to find 
the nitisinone and tyrosine levels at which the risk of 
later complications started to increase. Incidence was the 
number of TT1 patients divided with all live births. Gen-
eral birth data was provided by Statistics Finland [49]. 
Coefficient of variation (SD/mean) illustrated variability 
of blood tyrosine and nitisinone concentrations in each 
patient. Delayed diagnosis was considered to be a delay 
longer than the median of the study patients. Significance 
was defined as P value < 0.05. Analyses were performed 
using SPSS Statistics 25.0. (IBM Corp Armonk, NY).
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